复发难治性弥漫大B细胞淋巴瘤循环肿瘤DNA动态变化研究
该研究纳入29例接受铂类挽救化疗的复发难治性弥漫大B细胞淋巴瘤患者,分析124份血浆样本的ctDNA动态。基线FGA和ctDNA水平在治疗失败者中更高,中期评估时基线SNVs清除与应答改善相关,持续存在则预测失败。
要点
- 基线低FGA联合低MTV与良好结局相关。
- 中期评估时基线SNVs清除与应答改善相关,持续存在预测失败。
- 治疗结束达完全代谢缓解但ctDNA可检测的3例中2例复发。
核心结论
- ctDNA分析可作为复发难治性DLBCL的预后生物标志物及应答适应治疗策略的工具。
研究设计与样本
- 在格罗宁根大学医学中心开展,纳入29例接受铂类挽救化疗的复发难治性DLBCL患者,分析124份血浆样本。
- 采用低覆盖度全基因组测序检测拷贝数变异,并用115基因靶向测序检测单核苷酸变异和多核苷酸变异。
主要发现
- 治疗结束时完全缓解率为55%,1年无进展生存率为31%。
- 复发难治基线时,15例检测到CNAs,27例检测到SNVs,21例检测到MNVs。
- 治疗失败患者基线FGA和ctDNA水平更高。
- 中期评估时所有基线SNVs清除与应答改善相关,持续存在预测失败(p < 0.05)。
- 治疗结束达完全代谢缓解且ctDNA可检测的3例中2例复发。
关键数值与推荐
- 基线低FGA联合低MTV与良好结局相关。
- 中期评估时基线SNVs清除与应答改善相关,持续存在预测失败(p < 0.05)。
临床怎么用
- 可利用ctDNA动态监测复发难治性DLBCL的微小残留病变并指导应答适应治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The response to salvage chemotherapy in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) is poor, and data on circulating tumour deoxyribonucleic acid (ctDNA) in this setting are limited. We evaluated ctDNA dynamics in 29 patients with relapsed or refractory DLBCL who received platinum-based salvage chemotherapy at the University Medical Center Groningen. In total, 124 plasma samples were analysed using low-coverage whole-genome sequencing to detect copy number alterations (CNAs) and targeted sequencing with a 115-gene panel for single- and multi-nucleotide variants (SNVs/MNVs). The complete response rate at the end of treatment was 55%, with a 1-year progression-free survival of 31%. At the R/R baseline, defined as the time after confirmation of relapse or refractory status and prior to initiation of salvage chemotherapy, CNAs were detected in 15 patients, SNVs in 27 and MNVs in 21. Patients with treatment failure had higher fraction of genome altered (FGA) and ctDNA levels at baseline. Low FGA combined with low metabolic tumour volume (MTV) at baseline was associated with favourable outcome. Clearance of all baseline SNVs at interim evaluation correlated with improved response, while persistence predicted failure (p < 0.05). Two of three patients with complete metabolic response at the end of treatment and detectable ctDNA relapsed, indicating ctDNA as a sensitive marker of minimal residual disease. These findings indicate the value of ctDNA profiling as a prognostic biomarker and as a tool for response-adapted treatment strategies in R/R DLBCL.
引用
- Zhong Y, Bult J, Veltmaat N, et al. Dynamics of circulating tumour DNA in relapsed/refractory diffuse large B-cell lymphoma patients. Br J Haematol. 2025. PMID: 41410192. doi:10.1111/bjh.70296
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。